Multiple Sclerosis

Jessica, living with multiple sclerosis, Canada

Since 2011, Sanofi has rapidly emerged as a leader in multiple sclerosis (MS), an often-disabling disease of the central nervous system, which affects more than 2.3 million people worldwide.

MS is a chronic disease that affects each person differently, with symptoms ranging from numbness in the limbs or forgetfulness, to paralysis or loss of vision. MS is caused when the body’s immune system attacks the central nervous system, damaging the myelin sheath—the protective layer covering the nerves that carry signals between the brain and spinal cord and the rest of the body.

For over a decade, Sanofi has been working to develop novel treatments for MS. With two products currently in our MS franchise, we’re committed to maintaining long-term partnerships with patients, physicians, advocates, and researchers and making a significant impact on people living with MS.

A future focusing on protection and repair

Sanofi’s research and development efforts remain focused in areas where it has the strongest potential to help patients in need. This includes early-stage programs on preventing and repairing the damage to the nervous system caused by MS.

Inspired by patients around the world

  
Above from left to right: Anita, multiple sclerosis, France; Cassie, multiple sclerosis, Australia; Dave, multiple 
sclerosis, United Kingdom

Sanofi’s personalized approach

Sanofi recognizes that truly personalized medicine involves developing relationships with patients and caregivers, health care providers, and disease organizations and foundations.

Though MS affects a much larger population than lysosomal storage disorders, Sanofi’s vast experience working in rare diseases has given it a deep understanding of the experiences, challenges, and triumphs of those affected by this disease. Since the launch of our MS portfolio in 2011, Sanofi has cultivated close relationships with the MS community, providing strong patient support to those living with MS and engaging with the physicians treating this complex disease.